This article was originally published in The Gray Sheet
Sleuth AT advanced trending wireless, implantable cardiac monitoring system is rolling out after gaining 510(k) clearance Feb. 11, St. Paul, Minn., company announces March 4. Sleuth AT is a second-generation system that "allows physicians to program the capture of high quality electrocardiogram strips at frequent intervals, providing a new level of insight into complex arrhythmias which are often asymptomatic and frequently changing," according to Transoma. The first incarnation of Sleuth debuted in 2007
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”